Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evusheld in Hospitalized COVID-19 (ACTIV-3/TICO H4)
NCT05780437Phase 3Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Feb 2021
- Primary completion
- Jan 2022
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 3 trial of tixagevimab + cilgavimab in coronavirus disease 2019 (COVID-19), sponsored by National Institute of Allergy and Infectious Diseases. Started Feb 2021; status: completed.
02
Drugs
tixagevimab + cilgavimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05780437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05780437.